Quantinno Capital Management LP Invests $373,000 in Natera, Inc. (NASDAQ:NTRA)

Quantinno Capital Management LP bought a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 2,356 shares of the medical research company's stock, valued at approximately $373,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of NTRA. LRI Investments LLC purchased a new position in Natera during the 4th quarter valued at about $29,000. Blue Trust Inc. increased its holdings in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after purchasing an additional 97 shares during the period. EverSource Wealth Advisors LLC increased its holdings in Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after purchasing an additional 261 shares during the period. Principal Securities Inc. increased its holdings in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after purchasing an additional 59 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its holdings in Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after purchasing an additional 332 shares during the period. Institutional investors own 99.90% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on NTRA. Piper Sandler upped their target price on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. The Goldman Sachs Group upped their target price on Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. Robert W. Baird upped their target price on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Morgan Stanley upped their target price on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Finally, Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. According to MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and an average price target of $182.12.

Natera Stock Up 2.5%

NTRA stock traded up $3.84 during midday trading on Tuesday, hitting $157.16. The company's stock had a trading volume of 1,040,284 shares, compared to its average volume of 1,391,432. The company has a market cap of $21.46 billion, a PE ratio of -89.30 and a beta of 1.79. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm's 50-day moving average is $149.59 and its 200-day moving average is $158.04.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm's quarterly revenue was up 36.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.56) EPS. On average, equities research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity at Natera

In other news, CEO Steven Leonard Chapman sold 87,272 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the transaction, the chief executive officer now directly owns 203,354 shares of the company's stock, valued at $29,160,963.60. This represents a 30.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Solomon Moshkevich sold 6,000 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total value of $859,740.00. Following the transaction, the insider now directly owns 143,768 shares in the company, valued at $20,600,516.72. The trade was a 4.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 152,436 shares of company stock valued at $22,019,079. 7.60% of the stock is owned by corporate insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.